HCM
OKUR

Highbridge Capital Management’s OnKure Therapeutics OKUR Stock Holding History

Highbridge Capital Management’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-542,361
Closed -$1.57M – 408
2025
Q4 		$1.57M Sell
542,361
-107,857
-17% -$323K 0.05% 109
2025
Q3 		$1.79M Sell
650,218
-13,389
-2% -$33.2K 0.08% 103
2025
Q2 		$1.59M Buy
663,607
+224,810
+51% +$589K 0.06% 101
2025
Q1 		$1.89M Buy
438,797
+39,054
+10% +$220K 0.08% 80
2024
Q4 		$3.44M Buy
399,743
+93,474
+31% +$1.42M 0.13% 97
2024
Q3 		$5.21M Buy
306,269
+14,731
+5% +$218K 0.17% 93
2024
Q2 		$4.4M Buy
291,538
+17,881
+7% +$303K 0.14% 79
2024
Q1 		$4.54M Buy
273,657
+161,487
+144% +$2.66M 0.17% 85
2023
Q4 		$1.79M Buy
+112,170
New +$6.99M 0.07% 94

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Highbridge Capital Management's OKUR Position: Q1 2026 in Review

Highbridge Capital Management sold out of OnKure Therapeutics (OKUR) in Q1 2026, closing a stake of 542,361 shares — an estimated $1.57M sold.

Highbridge Capital Management first reported a position in OKUR in Q4 2023 and held it in 9 quarters. The position peaked at $5.21M in Q3 2024. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

  • Highbridge Capital Management reported no remaining OnKure Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Highbridge Capital Management sold 542,361 OnKure Therapeutics shares in Q1 2026, an estimated $1.57M.
  • Highbridge Capital Management first reported a position in OnKure Therapeutics in Q4 2023 and held it in 9 quarters.
  • Highbridge Capital Management's OnKure Therapeutics position peaked at $5.21M in Q3 2024.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Highbridge Capital Management's 13F filing for Q1 2026, filed 15 May 2026.